What the July 2026 FDA peptide vote did — and what it did not do

Reference page · published 2026-08-31

On July 23 and 24, 2026, an advisory committee to the U.S. Food and Drug Administration voted to recommend that six peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — be added to a list of bulk substances that compounding pharmacies are allowed to use. Since then the vote has been described in this market as an FDA clearance, an approval, and a change in the legal status of those compounds. It was none of those things. As of the date on this page, the list in question still contains six substances, none of which is a peptide; no rule adding any peptide to it has been proposed; and FDA's own scientific reviewers had recommended against adding all seven substances the committee considered.

That last point is the one almost entirely missing from the coverage, and it is written down in FDA's own briefing documents. This page sets out what the record actually says, quoting the primary documents and linking every one of them.

Disclosure: this index is operated by Artemis Labs, which sells several of the compounds named on this page as research reagents. That is a reason to check the primary sources here instead of taking our summary for it — every one is linked, and every quotation below is verbatim.

What actually happened

FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 at the agency's White Oak campus in Silver Spring, Maryland. The meeting was announced in the Federal Register on April 16, 2026, under docket number FDA-2025-N-6895 (91 FR 20465).

The subject was a specific legal question. Under the Federal Food, Drug, and Cosmetic Act, a pharmacy compounding under section 503A may only use a bulk drug substance that meets one of three conditions. The Federal Register notice states them:

“(1) comply with the standards of an applicable United States Pharmacopoeia (USP) or National Formulary monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (2) if an applicable monograph does not exist, are drug substances that are components of drugs approved by the Secretary of Health and Human Services (the Secretary); or (3) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, that appear on a list developed by the Secretary through regulations issued by the Secretary under section 503A(c) of the FD&C Act (the 503A Bulks List).”

Read the third route carefully, because it is where the whole question sits: the list is developed through regulations. Not through a meeting, and not through a vote.

The committee considered seven substances, each in two chemical forms — free base and acetate — which is why there were fourteen separate votes, not seven. FDA's own question document for the meeting puts each one in the same flat form: VOTE: Should BPC-157 (free base) be placed on the list? (FDA meeting questions).

The seven substances, and the uses FDA reviewed

Each substance was evaluated for a named use, not for the uses it is marketed for. The Federal Register notice sets them out in a table; this is that table, reproduced exactly.

The gap between that column and the marketplace is itself part of the record. Writing about the meeting, Joanne S. Hawana of the law firm Mintz noted that although each compound was assessed for one or more specific uses, in the wellness marketplace these peptides are promoted and sold for a wide array of diverse uses that have not been affirmed or even tested in large-scale human studies (Mintz, July 29, 2026). Nothing the committee voted on speaks to any use outside the middle column above.

FDA's own reviewers recommended against all seven

Before the meeting, FDA published a briefing document for each substance — seven compound-level reviews written by the agency's own pharmaceutical scientists, pharmacologists and consumer safety officers, running from 38 to 83 pages each. They are public, and they are the most detailed assessment of these compounds any regulator has published.

Every one of the seven reaches the same conclusion. The BPC-157 document, dated May 11, 2026, puts it this way:

“We have balanced the criteria described in section II above to evaluate BPC-157 (free base) and BPC-157 acetate for the 503A Bulks List. After considering the information currently available, a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on that list…” — FDA Briefing Document, BPC-157

The same sentence, with the substance name swapped, appears in the KPV, TB-500, MOTS-c, emideltide, semax and epitalon documents. Mintz summarised the position in one line: FDA's reviewers had recommended against including all seven peptides on the 503A affirmative list due to a lack of clinical data or sufficient characterization of the drugs, among other reasons.

So the committee did not ratify an FDA position. It voted against one.

What “not well characterized” means here

The characterization finding is repeated across the documents in nearly identical wording, and it is worth quoting because it is a chemistry finding, not a policy one. Of BPC-157, FDA wrote that it is

“considered not well-characterized from the physical and chemical characterization perspective based on (1) inconsistent naming conventions that do not follow established chemical nomenclature standards (e.g., USAN, INN, IUPAC), and (2) data/information relevant to certain CQAs for establishing its identity, purity, and quality for its intended use in the proposed dosage forms were either lacking or deemed to be inadequate in the nomination packages or not found in the publicly available scientific literature.”

“CQAs” are critical quality attributes — the measurable properties a material has to have for its intended use. FDA listed examples of what was missing: tests characterizing peptide-related impurities and aggregates, and microbial quality including bioburden and bacterial endotoxins.

The TB-500 review is blunter about where it looked and came up empty:

“Specific tests for TB-500 (free base) are not available in the public domain or in the publicly available CoA, such as tests for impurities, aggregates, microbiological quality, and bacterial endotoxin.” — FDA Briefing Document, TB-500

The emideltide review contains the sharpest single finding in the package. FDA examined the certificate of analysis the nominator submitted and found it internally inconsistent — the document did not agree with itself about which substance it described:

“The chemical name provided in CoA by the nominator does not correspond to the emideltide. The chemical name, Chemical Abstract Service (CAS) number, molecular formula, molecular weight, and amino acid sequence information provided by the nominator refers to emideltide (free base), but the chemical name and acetic acid content testing in CoA refers to emideltide acetate… It is unclear whether emideltide or emideltide acetate was intended to be the nominated BDS based on the information provided.” — FDA Briefing Document, Emideltide

That is a certificate of analysis submitted to a federal advisory proceeding, by a party asking for a favorable decision, that names one substance in its identity fields and a different one in its test results. It is a useful reminder of what a certificate of analysis is and is not — a document, produced by someone, that has to be read, not trusted. We have written separately about how to read a certificate of analysis and about what a purity number does and does not prove.

How thin the human evidence was

For BPC-157 evaluated in ulcerative colitis, FDA's reviewers described the clinical record they were able to find. Searching the literature, they reported: We identified a single meeting abstract reporting on the results of a multicenter, randomized, double blind, placebo-controlled study in subjects with UC — a conference abstract from 2005. The same document notes that the two major professional guidelines on managing the condition do not mention the compound: Neither of these guidelines mention BPC-157 in their recommendations for the management of UC.

FDA also recorded a safety concern that runs across several of the reviews — that the agency is concerned about the potential for immunogenicity of these peptides in certain dosage forms, because of possible aggregation and peptide-related impurities, adding that the stability, pharmacological activity, and immunogenic properties of peptides are highly sensitive to the manufacturing process and quality attributes of the compounded/finished drug product.

How the committee voted

FDA has not published minutes or a transcript of the meeting. As of the date on this page, the meeting's Event Materials section lists the briefing documents, the questions document and the committee roster, and nothing else. The vote counts below therefore come from press reporting, not from an FDA document, and are attributed accordingly.

Reporting on day one, Pharmaceutical Executive wrote: The 14-member Pharmacy Compounding Advisory Committee voted 8-6 in favor of allowing Bpc-157, Kpv and Tb-500 to be compounded, with one abstention, while Mots-c, which is being evaluated for obesity and osteoporosis, passed on a 7-5 vote, with two abstentions. The same report stated plainly that The votes came over the objections of FDA career scientists, who said they lacked the evidence to assess the compounds' safety and effectiveness (PharmExec, July 24, 2026).

Two law firms independently reported the two-day outcome. Mintz: the committee recommended that BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax be added to the 503A affirmative list. They voted against the addition of emideltide. McDermott Will & Schulte described the same result (client alert, July 27, 2026). We have not located a per-substance vote count for the July 24 session in any source we fetched, so none is stated here.

Why a recommendation is not a decision

FDA states the status of advisory committee output on the meeting page itself:

“Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” — FDA meeting page

And every one of the seven briefing documents opens with the agency saying the same thing about its own process:

“The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting.”

Dustin Robinson, a founding partner at LumaLex Law, described the sequence in the PharmExec report: there are three distinct legal events the market keeps treating as one, removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list following notice-and-comment rulemaking. He estimated that the rulemaking cycle realistically runs eight to twelve months before 503A pharmacies have unambiguous legal authority to compound these substances. Mintz put it in four words: Nothing has legally changed yet.

What the 503A Bulks List actually contains today

The list is not a policy document or a webpage. It is a regulation — 21 CFR 216.23 — and anyone can read the whole of it. As of the current text, it names six substances:

“(1) Brilliant Blue G, also known as Coomassie Brilliant Blue G-250. (2) Cantharidin (for topical use only). (3) Diphenylcyclopropenone (for topical use only). (4) N-acetyl-D-glucosamine (for topical use only). (5) Squaric acid dibutyl ester (for topical use only). (6) Thymol iodide (for topical use only).” — 21 CFR 216.23(a)

That is the entire list. No peptide appears on it. The regulation was last amended in 2019 (84 FR 4710). Nothing that happened in July 2026 changed a word of it.

Part 216 has a neighbour that does not exist yet. A proposed section 216.25 would create lists of products and whole categories that may not be compounded at all, under either compounding pathway, and it asks a different question from this one: what a compounder may produce rather than what it may start from. It names three categories, none of them a molecule — the list that would bar a drug from being compounded.

The same regulation contains a paragraph that deserves far more attention than it gets, because it answers the marketing question directly. Even for the six substances that did make the list, FDA wrote:

“Based on evidence currently available, there are inadequate data to demonstrate the safety or efficacy of any drug product compounded using any of the drug substances listed in paragraph (a) of this section… Any person who represents that a compounded drug made with a bulk drug substance that appears on this list is FDA approved, or otherwise endorsed by FDA generally or for a particular indication, will cause the drug to be misbranded under section 502(a) and/or 502(bb) of the Federal Food, Drug, and Cosmetic Act.” — 21 CFR 216.23(d)

In other words: being on the list does not make a substance FDA-approved, and saying that it does is itself a violation. A substance that is only recommended for the list by an advisory committee is two steps further back than that.

What has happened since the vote

We checked the Federal Register directly on the date of this page. Searching its full document database for 2026, the only published document mentioning BPC-157, MOTS-c or epitalon is the April 16, 2026 notice announcing that the meeting would take place. No proposed rule, and no final rule, adding any of these substances to the 503A Bulks List has been published. Until one is, the regulation quoted above is the law, unchanged.

Two law firms reading the same record disagree about what comes next, and the disagreement is worth knowing about. McDermott's alert states that FDA will initiate notice-and-comment rulemaking and adds that the agency is expected to exercise some form of informal enforcement discretion in the interim. Mintz is more cautious, writing that how FDA proceeds remains to be seen. Neither is a statement of what FDA has done, because FDA has not announced what it will do.

Mintz also reports that a second PCAC meeting, covering an additional five peptides, is expected to be scheduled in February 2027.

A separate question sits underneath the bulks list and did not come up at the meeting. The 503A pathway is a set of exemptions from the drug approval requirements, and a molecule longer than 40 amino acids is not only a drug — it is a biological product under a different statute, which the bulks list does not reach. None of the seven substances voted on is anywhere near that length, so the point did not arise here. It arises for the longer compounds, and it is set out at the 40-amino-acid line between a peptide and a biologic.

One consequence that cuts against the sellers

A favorable committee vote is being read in this market as permission to make stronger claims. The Mintz analysis points out that the public record created by the meeting does the opposite:

“Federal and state advertising and consumer protection laws generally require ‘competent and reliable scientific evidence’ to support claims about health products, and as now documented in the public record for the PCAC meeting, there is no such evidence supporting any health-related claims for these unapproved peptides.”

The seven briefing documents are now the most authoritative published statement of how thin the evidence is. A vendor citing the vote as support for a claim is citing a proceeding whose written record says the evidence for that claim was inadequate.

What does the evidence not show?

The limits of this page, stated plainly.

1. The vote counts here are press reporting, not an FDA record. FDA has published no minutes or transcript. If the agency posts them, the counts should be checked against them and this page corrected.
2. An FDA reviewer recommendation is also not a determination. The briefing documents say so themselves. FDA's staff recommending against these substances is not the agency rejecting them, any more than the committee's vote was the agency accepting them.
3. “Not well characterized” is a statement about the published record, not about any particular vial. FDA's finding is that the identity, purity and quality data needed for a specific compounding use were missing from the nomination packages and from the public literature. That is not a measurement of any material sold by anyone, including us.
4. FDA evaluated named uses only. The reviews assess each substance for the use in the table above. They are not an evaluation of, or a comment on, any other use.
5. The conflict-of-interest reporting is press attribution, not our finding. PharmExec, citing Reuters, reported that eight of the fourteen members were recently appointed, and that six of the new appointees operate or work for clinics that offer peptide treatments. We have not independently verified the committee's composition or any member's interests, and we make no claim about them. We note it because the reporting exists and readers will meet it elsewhere.
6. The nominators were commercial parties. FDA's BPC-157 briefing document lists the nominations it evaluated as coming from LDT Health Solutions Inc. and Wells Pharmacy Network. Substances reach this process because someone asks for them, and who asked is part of the record.
7. This page is about a regulatory proceeding. It is not a claim that any compound is safe, effective, useful, or suitable for anything. FDA's reviewers concluded the evidence did not support adding these substances for the uses proposed, and this page reports that conclusion, and does not argue with it.

Sources

Every document below was retrieved and read in full on 2026-08-31.

• Pharmacy Compounding Advisory Committee; Notice of Meeting… — 91 FR 20465, April 16, 2026; Docket FDA-2025-N-6895
• FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
• FDA, PCAC meeting questions (voting questions, both days)
• FDA Briefing Document — Introduction
• FDA Briefing Document — BPC-157 (68 pp.)
• FDA Briefing Document — KPV (38 pp.)
• FDA Briefing Document — TB-500 (41 pp.)
• FDA Briefing Document — MOTS-c (44 pp.)
• FDA Briefing Document — Emideltide (83 pp.)
• FDA Briefing Document — Semax (69 pp.)
• FDA Briefing Document — Epitalon (64 pp.)
• 21 CFR 216.23 — the 503A Bulks List, as published in the Code of Federal Regulations
• Federal Register document search API — queried 2026-08-31 for rulemaking on these substances; none found beyond the meeting notice
• Nicholas Jacobus, “FDA Panel Votes to Loosen Restrictions for Four Peptides,” Pharmaceutical Executive, July 24, 2026
• Joanne S. Hawana, “FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do,” Mintz, July 29, 2026
• “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting,” McDermott Will & Schulte, July 27, 2026

Related pages in this index: how to read a certificate of analysis, what an HPLC purity number proves, what a lot number proves, the 2020 Tailor Made Compounding letter (a licensed pharmacy told, under the same subsection, that six of these substances could not be compounded), and the vendor landscape.

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.